BACKGROUND: Influenza vaccine immunogenicity in premature infants is incompletely characterized. OBJECTIVE: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤ 1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (≥ 37 week) infants. DESIGN/ METHODS: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. RESULTS: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers ≥ 1:32 to B/Victoria (85% vs. 60%, P = 0.04) in 2007-2008. Two (5%) premature and 8 (19%) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. CONCLUSIONS: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.
BACKGROUND:Influenza vaccine immunogenicity in premature infants is incompletely characterized. OBJECTIVE: To assess the immunogenicity of trivalent, inactivated influenza vaccine (TIV) in extremely low-birth-weight (≤ 1000 g birth weight) premature (<30 weeks gestation) infants. We hypothesized that geometric mean titers of influenza antibody would be lower in premature than in full-term (FT) (≥ 37 week) infants. DESIGN/ METHODS: In this prospective multicenter study, former premature and FT infants who were 6 to 17 months of age received 2 doses of TIV during the 2006-2007 or 2007-2008 influenza seasons. Sera were drawn before dose 1, and 4 to 6 weeks after dose 2. Antibody was measured by hemagglutination inhibition. RESULTS: Over 2 years, 41 premature and 42 FT infants were enrolled; 36 and 33 of these infants, respectively, had postvaccination titers available. Premature infants weighed less (mean, 1.3-1.8 kg difference) at the time of immunization than FT infants. Prevaccination titers did not differ between groups. Premature infants had higher postvaccination antibody geometric mean titers than FT infants to H1 (2006-2007, 1:513 vs. 1:91, P = 0.03; 2007-2008, 1:363 vs. 1:189, P = 0.02) and B/Victoria (2006-2007, 1:51 vs. 1:10, P = 0.02). More premature than FT infants had antibody titers ≥ 1:32 to B/Victoria (85% vs. 60%, P = 0.04) in 2007-2008. Two (5%) premature and 8 (19%) FT infants had adverse events, primarily fever, within 72 hours after vaccination. No child had medically diagnosed influenza. CONCLUSIONS: Former premature infants had antibody responses to 2 TIV doses higher than or equal to those of FT children. Two TIV doses are immunogenic and well tolerated in extremely low-birth-weight, premature infants 6 to 17 months old.
Authors: Janice K Louie; Shilpa Gavali; Meileen Acosta; Michael C Samuel; Kathleen Winter; Cynthia Jean; Carol A Glaser; Bela T Matyas; Robert Schechter Journal: Arch Pediatr Adolesc Med Date: 2010-11
Authors: Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Melonie Heron; Paul D Sutton; Jiaquan Xu; Stephanie J Ventura; Donna M Strobino; Bernard Guyer Journal: Pediatrics Date: 2009-12-21 Impact factor: 7.124
Authors: Janet A Englund; Emmanuel Walter; Steven Black; Mark Blatter; Jack Nyberg; Frederick L Ruben; Michael D Decker Journal: Pediatr Infect Dis J Date: 2010-02 Impact factor: 2.129
Authors: Emmanuel B Walter; Janet A Englund; Mark Blatter; Jack Nyberg; Frederick L Ruben; Michael D Decker Journal: Pediatr Infect Dis J Date: 2009-12 Impact factor: 2.129
Authors: Peter G Szilagyi; Gerry Fairbrother; Marie R Griffin; Richard W Hornung; Stephanie Donauer; Ardythe Morrow; Mekibib Altaye; Yuwei Zhu; Sandra Ambrose; Kathryn M Edwards; Katherine A Poehling; Geraldine Lofthus; Michol Holloway; Lyn Finelli; Marika Iwane; Mary Allen Staat Journal: Arch Pediatr Adolesc Med Date: 2008-10
Authors: Katherine W Eisenberg; Peter G Szilagyi; Gerry Fairbrother; Marie R Griffin; Mary Staat; Laura P Shone; Geoffrey A Weinberg; Caroline B Hall; Katherine A Poehling; Kathryn M Edwards; Geraldine Lofthus; Susan G Fisher; Carolyn B Bridges; Marika K Iwane Journal: Pediatrics Date: 2008-11 Impact factor: 7.124
Authors: Timothy P Welliver; Roberto P Garofalo; Yashoda Hosakote; Karen H Hintz; Luis Avendano; Katherine Sanchez; Luis Velozo; Hasan Jafri; Susana Chavez-Bueno; Pearay L Ogra; LuAnn McKinney; Jennifer L Reed; Robert C Welliver Journal: J Infect Dis Date: 2007-03-09 Impact factor: 5.226
Authors: Carl T D'Angio; Claire P Wyman; Ravi S Misra; Jessica L Halliley; Hongyue Wang; Julianne E Hunn; Caitlin M Fallone; F Eun-Hyung Lee Journal: Vaccine Date: 2017-08-12 Impact factor: 3.641
Authors: John F Alcorn; Raghunandan Avula; Anish B Chakka; William E Schwarzmann; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Marianna A Ortiz; William T Horne; Uma R Chandran; Jennifer P Nagg; Richard K Zimmerman; Kelly S Cole; Krissy K Moehling; Judith M Martin Journal: Hum Vaccin Immunother Date: 2020-04-16 Impact factor: 3.452
Authors: Christoph Härtel; Alexander Humberg; Dorothee Viemann; Anja Stein; Thorsten Orlikowsky; Jan Rupp; Matthias V Kopp; Egbert Herting; Wolfgang Göpel Journal: Front Pediatr Date: 2016-11-30 Impact factor: 3.418